Mirati Therapeutics, Inc.
http://mirati.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mirati Therapeutics, Inc.
Ipsen Outpaces Market With Lucrative Priority Review Voucher Deal
The going rate to buy a voucher for a faster US FDA application review is about $100m, but the France-headquartered firm received considerably more from an unnamed big pharma.
Ipsen Outpaces Market With Lucrative Priority Review Voucher Deal
The going rate to buy a voucher that speeds up a regulatory review in the US is about $100m but the France-headquartered firm has managed to get considerably more from an unnamed big pharma.
Five Recent Deals Show ADCs Aren’t Cooling Off For Summer
While 2024 has seen two buyouts of antibody-drug conjugate specialists with $1bn-plus price tags, the focus on ADCs has continued, accounting for almost half of recent oncology deals.
Device Classifications For COVID, Acute Febrile Illness IVDs And Force Separation Catheters
The FDA designated class II special controls classifications for two diagnostics and force separation catheters.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- MethylGene Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice